Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)

Chronic Hepatitis C Clinical Trial

Official title:

A Randomized Clinical Trial Using Fine Needle Aspiration For Evaluation of Hepatic Pharmacokinetics of MK-5172 in Participants With Chronic Hepatitis C

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01547312
• Other study ID #: 5172-022
• Secondary ID: 2011-004978-29
• Status: Withdrawn
• Phase: Phase 1
• First received: February 2, 2012
• Last updated: October 13, 2015
• Start date: May 2012
• Est. completion date: November 2012

Study information

• Verified date: October 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study is divided into 2 segments, and proposes to qualify fine needle aspiration (FNA) as a platform to evaluate the hepatic pharmacokinetics of low and high oral doses of Grazoprevir (MK-5172) in non-cirrhotic participants chronically infected with hepatitis C virus (HCV). The first segment, is a procedural pilot conducted prior to the main study, that is aimed at ensuring optimal execution of the FNA procedure. During the procedural pilot, core needle biopsy (CNB) will be performed on participants as part of their standard of care, but no study drugs will be administered, nor will any procedures other than FNA be conducted. The second segment, the main study, is designed to evaluate the feasibility of measuring Grazoprevir by FNA. During the main study, drugs will be administered, and other additional procedures will be conducted.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 2012
• Est. primary completion date: November 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Has chronic compensated HCV infection.

• No contraindications to CNB or FNA procedures.

• Pilot study only: All comers with chronic HCV already scheduled to undergo CNB for fibrosis staging.

• Pilot study only: Requires a diagnostic liver biopsy to monitor progression of liver disease.

• Pilot study only: Does not have cirrhosis.

• Main study only: Males or non-pregnant and postmenopausal females willing to use medically acceptable contraception during, and for 6 months or longer after study.

• Main study only: Body mass index of 18.5 - 32.0 kg/m^2.

• Main study only: Can avoid aspirin, anticoagulants, and non steroidal inflammatory agents.

• Main study only: Has undergone prior treatment or is treatment naive for chronic HCV infection.

Exclusion Criteria for Main study only:

• History of any of the following: stroke, chronic seizures, major neurological disorders, gastric bypass surgery or bowel resection.

• No viral response to prior interferon based therapy.

• Prior treatment for HCV with an NS3/4A protease inhibitor.

• History of either clinically significant, uncontrolled endocrine, gastrointestinal, cardiovascular, hematological, immunological, renal, respiratory, or genitourinary abnormalities/diseases.

• History of neoplastic or myeloproliferative disease.

• Has any of the following : cirrhosis, decompensated liver disease, or other advanced liver disease, hepatocellular carcinoma, infection with human immunodeficiency virus (HIV), or hepatitis B.

• Evidence of high grade bridging fibrosis from prior liver biopsy or chronic hepatitis not caused by HCV.

• History of illicit drug use or alcohol abuse.

• Had surgery, donated at least one unit of blood, or participated in any other investigational study within 4 weeks prior to screening visit.

• History of multiple and/or severe allergies.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Chronic Hepatitis C
• Hepatitis
• Hepatitis A
• Hepatitis C
• Hepatitis C, Chronic
• Hepatitis, Chronic

Intervention

Drug:
• Peg-Interferon
Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.

Procedure:
• Liver Samples from FNA
Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.
• Liver Samples from CNB
Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
• Blood Samples
Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.

Drug:
• Ribavirin
Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.
• 800 mg Grazoprevir
800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
• 100 mg Grazoprevir
100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.

Procedure:
• Liver samples from CNB and FNA
Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants from whom detectable concentrations of hepatic Grazoprevir are obtained by FNA.		Days 7-12.	No